Related Experiment Video
Updated: Jan 21, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
mGlu2/3 receptor antagonists
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Yoshino-cho, Saitama, Japan.
Metabotropic (mGlu) 2/3 receptor antagonists show promise for treating depression and anxiety. Their antidepressant effects, similar to ketamine, warrant further investigation as novel therapeutic agents.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Glutamatergic transmission abnormalities are linked to neuropsychiatric disorders.
- Metabotropic (mGlu) 2/3 receptors are emerging molecular targets for treating depression and anxiety.
Purpose of the Study:
- To review the pharmacology of mGlu 2/3 receptor antagonists.
- To evaluate their therapeutic potential, particularly as novel antidepressants.
Main Methods:
- Synthesis and examination of orthosteric and allosteric mGlu 2/3 receptor antagonists.
- Review of existing research on their therapeutic applications.
Main Results:
- mGlu 2/3 receptor antagonists demonstrate therapeutic promise for neuropsychiatric disorders.
- Their antidepressant effects and mechanisms resemble those of ketamine.
Conclusions:
- mGlu 2/3 receptor antagonists are promising candidates for novel antidepressant therapies.
- Their efficacy warrants comparison with established treatments like ketamine.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
07:09Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
Published on: September 8, 2011
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...